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Introduction: Vitamin Dmay affect multiple health outcomes. If so, an effect on mortality is to be
expected. Using pooled data from randomized controlled trials, we performed individual patient
data (IPD)andtrial levelmeta-analyses toassessmortalityamongparticipants randomizedtoeither
vitamin D alone or vitamin D with calcium.
Subjects and Methods: Through a systematic literature search, we identified 24 randomized con-
trolled trials reportingdataonmortality inwhich vitaminDwasgiven either aloneorwith calcium.
From a total of 13 trials with more than 1000 participants each, eight trials were included in our
IPD analysis. Using a stratified Cox regression model, we calculated risk of death during 3 yr of
treatment inan intention-to-treat analysis.Also,weperformeda trial levelmeta-analysis including
data from all studies.
Results: The IPD analysis yielded data on 70,528 randomized participants (86.8% females) with a
median age of 70 (interquartile range, 62–77) yr. Vitamin D with or without calcium reduced
mortality by 7% [hazard ratio, 0.93; 95% confidence interval (CI), 0.88–0.99]. However, vitamin D
alone did not affect mortality, but risk of death was reduced if vitamin D was given with calcium
(hazard ratio, 0.91; 95% CI, 0.84–0.98). The number needed to treat with vitamin D plus calcium
for 3 yr to prevent one death was 151. Trial level meta-analysis (24 trials with 88,097 participants)
showed similar results, i.e.mortalitywas reducedwith vitaminDplus calcium (odds ratio, 0.94; 95%
CI, 0.88–0.99), but not with vitamin D alone (odds ratio, 0.98; 95% CI, 0.91–1.06).
Conclusion:VitaminDwith calcium reducesmortality in the elderly, whereas available data do not
support an effect of vitamin D alone. (J Clin Endocrinol Metab 97: 0000–0000, 2012)
During the last decade, there has been increasing rec-ognition of the potential role of vitamin D in a large
number of tissues, where vitamin D receptors have been
identified. Thus, maintenance of adequate vitamin D sta-
tus may be necessary for many physiological functions,
beyond that of the classical actions of vitamin D on bone
andmineralmetabolism.Cross-sectional and longitudinal
studies have linked reduced vitamin D status with a num-
ber of cancers, adverse cardiovascular and immunological
outcomes, and increased all-cause mortality, although
some observational data have suggested either U-shaped
or reverse J-shaped relationships (1–3).
A meta-analysis of randomized controlled trials of vi-
tamin D supplementation published in 2007 found that
vitaminDreducedall-causemortalityby7%(relative risk,
0.93; 95%CI, 0.87–0.99) (4).However, three subsequent
meta-analyses using updated searches and different study
inclusion criteria failed to show a statistically significant
effect of vitamin D alone on mortality (2, 5, 6), although
two of the studies did show a reduced mortality if vitamin
Dwas given togetherwith calcium (5, 6). Study levelmeta-
analyses using summary data may be adequate when es-
timating a single treatment effect or investigating study
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level characteristics but may lead to biased assessments
and have limitations in explaining heterogeneity. To in-
vestigate whether treatment effects are related to patient
characteristics, individual patient data (IPD) analyses of-
fer advantages and have greater statistical power than
study level meta-analyses (7).
We recently published results of an IPD level meta-
analysis showing that vitamin D in doses of 10–20 g/d
given alone were not effective in fracture prevention, but
when givenwith calcium reduced fracture incidence (8). In
the present study, we aimed to investigate effects of vita-
min D supplementation, given either alone or with cal-
cium,onall-causemortalityusingboth IPD level and study
level meta-analysis methodologies.
Materials and Methods
Searching and selection criteria
As previously detailed, we undertook a systematic literature
search for publications between 1966 and 2008 inMedline, Em-
base, and the Cochrane Central Register of Controlled Trials on
the effects of vitamin D treatment on the risk of fracture (8). No
language restrictions were applied. We included only random-
ized (individual or cluster) controlled studies in which cholecal-
ciferol (vitamin D3) or ergocalciferol (vitamin D2) was given in
at least one intervention arm and with one arm without vitamin
D. For the IPD analysis, we excluded studies with less than 1000
participants (nine trials) due to concerns that studies with fewer
participants, although contributing additional cases, would also
further reduce the mass of shared study variables for aggregated
analysis. The search revealed 11 eligible studies (9–19). For the
present analysis, we updated our search to January 2011 and
included theMeSH terms: [death,mortality], thereby identifying
two further eligible studies (20, 21). Five study groups were un-
willing or unable to provide patient level data (9, 10, 12, 16, 17),
leaving eight studies for IPD analysis (Table 1). All studies had
incident fractures as the primary endpoint, whereas data on
death were collected as secondary endpoints during follow-up
(14, 15, 18–20) and/or by the use of national registers of vital
statistics (11, 13, 15, 19, 21).
Analytical approach
We defined base models using unconditional logistic re-
gression incorporating age and sex, which we expected a pri-
ori to contribute to variation in mortality. We also included
data on incident major osteoporotic fracture during the study,
i.e. fractures at the hip or spine because mortality is known to
be increased after such fractures, and information on the use
of postmenopausal hormone replacement therapy (HRT) and
bisphosphonates. Analysis on mortality was performed using a
stratified Cox regression model, with the clinical study as stra-
tum, thereby ensuring that like was compared with like, because
the inference is based on the randomization of patients within
each trial. We added treatment allocation and interaction terms
to this model to study effects of vitamin D vs. no vitamin D
supplements on risk of death. Interaction terms studied included
age, sex, and daily dose of vitaminD. In studieswith intermittent
(monthly or yearly) administration of vitamin D, an equivalent
daily dose was calculated. In all analyses, observations were
truncated after 36 months (1095 d) because few of the studies
provided substantial data beyond this time point. However, to
evaluate the effect of interventions during the entire duration of
trials, we also performed logistic regression analyses with treat-
ment allocation added to the base model. All analyses were per-
formed using an intention-to-treat approach including all ran-
domized participants.
Prespecified subanalyses
Three prespecified analyses were performed:
1. Because ergocalciferol may have a shorter half-life than
cholecalciferol and lower systemic availability if injected
im (22), we studied the effects of cholecalciferol separately
and addressed the impact of vitamin D dose on mortality
by regrouping the Smith et al. (18) study (average, 20.5g
ergocalciferol/d) with 10-g cholecalciferol studies.
2. Whether vitamin D was administered alone or with cal-
cium supplements (CaD) and whether daily vs. intermit-
tent administration affected results.
3. In the RECORD study, one of the treatment arms had
calciumas stand-alone treatment, i.e.without concomitant
vitamin D (15). A priori, participants randomized to the
calcium-alone group were considered as belonging to the
placebo/non-vitamin D group. However, because recent
studies have suggested detrimental effects of calcium-alone
treatment (23), analyseswere also performed inwhich par-
ticipants randomized to the calcium-alone group were re-
moved from the analyses.
Sensitivity
To assesswhether our conclusionswould have beenmodified
by failure to include one or more individual studies, we per-
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TABLE 1. Characteristics of the eight randomized controlled trials included in the IPD analysis and 16 additional
studies included in the trial level meta-analysis
First author, year (Ref.)
Patient category; total no. of
included participants (%
females); median age (IQR) or
mean  SD; place of study
Randomization
and duration
Study arms; no. of participants in
each arm/total no. of deaths
during the entire period of follow-
upa (no. of deaths during the first
36 months of follow-upb)
Studies included in IPD analysis
Meyer, 2002 (11) Nursing home residents; n 
1,144 (75.9%); age, 85 (81–90)
yr; Norway
Q, 24 months,
double-blind
Daily oral 10 g D3, 569/246 (246), vs.
placebo, 575/245 (245)
Larsen, 2004 (13) Community-dwelling aged 66 yr;
n  9,605 (60.1%); age, 74
(70–79) yr; Denmark
C, 42 months,
open-label
Daily oral 10 g D3  1000 mg Ca,
4,957/832 (715), vs. no treatment,
4,648/839 (705)
Porthouse, 2005 (14) GP patients with risk factors for
fracture; n  3,314 (100%);
age, 76 (73–80) yr; UK
I, 18–42 (median,
22.5) months,
open-label
Daily oral 20 g D3  1000 mg Ca.
1,321/57 (57), vs. leaflet, 1,993/68
(67)
Grant (RECORD), 2005 (15) Previous osteoporotic fracture; n 
5,292 (84.7%); age, 77 (73–81)
yr; UK
I, 24–62 (median,
30.4) months,
double-blind
Four groups with daily oral dose: 1) 20
g D3  1000 mg Ca, 1,306/221
(161); 2) 20 g D3, 1,343/217 (167);
3) 1000 mg Ca, 1,311/243 (198); 4)
double placebo, 1,332/217 (172)
Smith, 2007 (18) GP patients presenting for
influenza vaccination; n  9,440
(53.9%); age, 79 (77–83) yr; UK
I, up to 36 (median,
36.0) months,
double-blind
Once a year im 300,000 IU D2, 4,727/
316 (290), vs. placebo, 4,713/312
(291) (equal to an average D2 dose
of 20.5 g/d)
LaCroix (WHI), 2009 (19)c Community-based
postmenopausal women; n 
36,282 (100%); age, 62 (57–68)
yr; USA
I, median, 85.4
months, double-
blind
Daily oral 10 g D3  1000 mg Ca,
18,176/755 (180), vs. placebo,
18,106/825 (220)
Sanders, 2010 (20)e Community-dwelling aged 70 yr;
n  2,256 (100%); age, 76 (73–
80) yr; Australia
I, up to 60 (median,
36) months,
double-blind
Once a year oral 500,000 IU D3, 1,131/
46 (39), vs. placebo, 1,125/54 (46)
(equal to an average D3 dose of 34
g/d)
Salovaara (OSTPRE-FPS),
2010 (21)d
Community-dwelling women aged
65–71 yr; n  3,195 (100%);
age, 67 (66–69) yr; Finland
I, up to 36 months;
mean follow-up
time, 3.01 (SD,
0.22) yr, open-
label
Daily oral 20 g D3  1000 mg Ca,
1,586/15 (15), vs. no treatment,
1,609/18 (18)
Additional medium- and large-
sized (500 participants)
studies included in trial
level meta-analysis
Chapuy, 1994 (9) Nursing home residents; n 
3,270 (100%); age, 84  6 yr;
France
I, up to 36 months,
double-blind
Daily oral 20 g D3  1200 mg Ca,
1,634/601, vs. placebo, 1,636/597
Lips, 1996 (10) Living independently, in
apartments/homes for elderly
persons aged 70 yr; n  2,578
(74%); age, 80  6 yr; The
Netherlands
I, up to 42 months,
double-blind
Daily oral 10 g D3, 1,291/223, vs.
placebo, 1,287/251
Chapuy, 2002 (27) Ambulatory institutionalized
women; n  583 (100%); age,
85  7 yr; France
I, up to 24 months,
double-blind
Daily oral 20 g D3  1200 mg Ca,
393/71, vs. placebo, 190/45
(Continued)
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TABLE 1. Continued
First author, year (Ref.)
Patient category; total no. of
included participants (%
females); median age (IQR) or
mean  SD; place of study
Randomization
and duration
Study arms; no. of participants in
each arm/total no. of deaths
during the entire period of follow-
upa (no. of deaths during the first
36 months of follow-upb)
Trivedi, 2003 (12) Community-dwelling aged 65 yr;
n  2,686 (24%); age, 75  5
yr; UK
I, up to 60 months,
double-blind
Every fourth month, oral 100,000 IU
D3, 1,345/224, vs. placebo, 1,341/
247 (equal to an average D3 dose of
21 g/d)
Flicker, 2005 (28) Nursing home residents; n  625
(95%); age, 83  8 yr; Australia
I, up to 24 months,
double-blind
Daily oral 600 mg Ca  D2, initially
10,000 IU weekly followed by 25
g/d, 313/76, vs. placebo, 312/85
Law, 2006 (16)f Nursing home residents; n 
2,641 (76%); mean age, 85 yr;
UK
C, median, 10 (IQR,
7–14) months,
open-label
Every third month, oral 100,000 IU D2,
1,252/247, vs. placebo, 1,389/229
(equal to an average D2 dose of 28
g/d)
Lyons, 2007 (17) Nursing home residents; n 
3,440 (76%); age, 84  8 yr; UK
I, up to 36 months,
double-blind
Every fourth month, oral 100,000 IU
D2, 1,673/713, vs. placebo, 1,670/
715 (equal to an average D2 dose of
21 g/d)
Small-sized studies (500
participants) included in
trial level meta-analysis
Baeksgaard, 1998 (29) Healthy women aged 58–67 yr;
n  240 (100%); mean age, 62
yr; Denmark
I, 24 months,
double-blind
Daily oral 14 g D3  1000 mg Ca,
160/1, vs. placebo, 80/1
Krieg, 1999 (43) Institutionalized women aged 62–
98 yr; n  248 (100%); age, NA;
Switzerland
I, 24 months, open-
label
Daily oral 22 g D3  1000 mg Ca,
124/21, vs. no treatment, 124/26
Komulainen, 1999 (44) Early postmenopausal women; n 
458 (100%); mean age, 53 yr
(Finland)
I, 60 months, open-
label
Four treatment groups with daily oral:
1) HRT, 115/1; 2) 7.5 g D3 (only 2.5
g/d during the fifth year), 112/0; 3)
HRT  D3 as above, 116/1; 4)
placebo, 115/1
Latham, 2003 (30) Frail elderly aged 65 yr; n  243
(53%); age, 79  7 yr; New
Zealand
I, 6-month follow-
up, double-blind
Single oral dose 300,000 IU D3, 121/
11, vs. placebo, 122/3
Avenell, 2004 (45) Aged 70 yr and a history of an
osteoporotic fracture within the
last 10 yr; n  134 (82%); age,
77  5 yr; UK
I, 12 months, open-
label
Daily oral 20 g D3  1000 mg Ca,
99/1, vs. no treatment, 35/1
Harwood, 2004 (46) Elderly with a recent hip fracture;
n  150 (100%); age, 81 (67–
92) yr; UK
I, 12 months, open-
label
Four study groups: 1) single injection
of D2 300,000 IU, 38/7; 2) single
injection D2 300,000 IU  1000 mg/
d Ca, 36/11; 3) oral D3 20 g/d 
1000 mg/d Ca, 39/6; 4) no
treatment, 37/5
Meier, 2004 (47) Healthy community dwelling aged
33–78 yr; n  55 (65%); age,
NA; Germany
I, 12 months, open-
label
Daily oral 12.5 g D3  500 mg Ca,
30/0, vs. no treatment, 25/1
Brazier, 2005 (31) Women 65 yr with plasma
25OHD 30 nmol/liter; n  192
(100%); age, 75  7 yr; France
I, 12 months,
double-blind
Daily oral 20 g D3  1000 mg Ca,
95/3, vs. placebo, 97/1
(Continued)
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formed an influence analysis in which studies were removed one
by one. To evaluate whether the lack of data from trials not
included in the IPDanalysis affected results, we performed a trial
level meta-analysis including all available studies (n  24) as
detailed inTable 1.Number of deaths by treatment allocation up
to 3 yr in the study by Chapuy et al. (9) was reported by personal
communication (Prof. P.Meunier, July 2010). In the cluster ran-
domized trial by Law et al. (16), adjustments to the number of
participants with outcomes and denominators were made using
an intraclass correlation coefficient of 0.026 derived from Dyer
et al. (24) using methods described by Higgins and Green (25).
All meta-analyses were performed stratified by whether vitamin
D was administered alone or in combination with calcium and
without the assumption of a common among-study variance
component across subgroups. The manuscript was prepared in
accordance with the PRISMA guidelines (26). Analyses were
undertaken using SPSS version 15 (SPSS Inc., Chicago, IL) and
Comprehensive Meta-analysis version 2.2 (Biostat, Englewood,
NJ). All tests were two-tailed. We considered P  0.05 as
significant.
Results
IPD analyses
Our IPD analysis included 70,528 randomized partic-
ipants (86.8% females) aged 48–103 (median, 70; inter-
quartile range, 62–77) yr. A total of 27,345were random-
ized toCaDand7,771 tovitaminDalone,whereas35,412
received placebo/no vitamin D.
Defining the base model
During the 36months of follow-up, 3832 (5.4%) study
participants died, and 1139 (1.6%) sustained an osteopo-
rotic fracture at the hip or spine. At baseline, 970 (1.4%)
reported the use of bisphosphonates. Among females,
20,402 (33.9%) were treated with HRT. This was mainly
due to the high proportion of HRT users in the Women’s
Health Initiative (WHI) (50.7%) and the OSTPRE-FPS
(48.5%) studies, whereas the frequency of HRT use in the
other studies was low (2.3%). After mutual adjustments,
the risk of death was significantly associated with increas-
ing age [hazard ratio (HR) per decade, 1.87; 95% CI,
1.78–1.96],male sex (HR, 1.52; 95%CI, 1.41–1.64), and
an incident major osteoporotic fracture during follow-up
(HR, 1.47; 95% CI, 1.27–1.69), whereas mortality was
FIG. 1. IPD analysis on survival in participants randomized to vitamin D
with or without calcium supplements compared with placebo/no
supplements. Data represent adjusted HR (95% CI).
TABLE 1. Continued
First author, year (Ref.)
Patient category; total no. of
included participants (%
females); median age (IQR) or
mean  SD; place of study
Randomization
and duration
Study arms; no. of participants in
each arm/total no. of deaths
during the entire period of follow-
upa (no. of deaths during the first
36 months of follow-upb)
Schleithoff, 2006 (32) Patients with congestive heart
failure; n  123 (17%); median
age, 55 yr; Germany
I, 9 months,
double-blind
Daily oral 50 g D3  500 mg Ca, 61/
7, vs. 500 mg Ca, 62/6
I, Individually randomized; Q, quasi-randomized by birth date; C, cluster randomized; IQR, interquartile range; 25OHD, 25-hydroyvitamin D; GP,
general practice; Ca, calcium supplement; NA, not available. To convert micrograms of vitamin D into international units, multiply by 40.
a Total number of deaths during the entire follow-up period, i.e. not restricted to the 36 months of follow-up used in the IPD analysis.
b Data only available for studies included in the IPD analysis.
c Number of deaths is based on the WHI Investigator Data Set updated on September 12, 2005 (released on December 21, 2006), in which slightly
more (n  29) deaths have been recorded than in the original trial report.
d Number of deaths is based on an updated data extraction (October, 2010) from the Finnish National Population Register in which slightly more
(n  5) deaths have been recorded than in the original trial report.
e Number of deaths in the original trial report was based on subjects who died while actively participating, whereas the number of deaths stated in
the table is based on treatment allocation independently of whether subjects participated actively or not in the study.
f Adjustments to the number of participants (1762 vs. 1995) with outcomes, and denominators in study were made using an intraclass correlation
coefficient of 0.026—see Sensitivity section for further explanations.
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not significantly affected by use of HRT (HR, 0.88; 95%
CI, 0.75–1.04) or bisphosphonates (HR, 0.60; 95% CI,
0.32–1.10).
Differences in mortality rates were not fully explained
by differences in age, sex, number of incident major os-
teoporotic fractures, or treatment with bisphosphonates
or HRT. Accordingly, analyses were performed adjusted
for age, sex, incidentmajorosteoporotic fractures, anduse
of bisphosphonates or HRT and stratified by study.
Effects of vitamin D supplementation with or
without calcium on risk of death
Within the group of participants randomized to vita-
min D with or without calcium (n  35,116), 1,870
(5.3%) died during follow-up, whereas death occurred in
1,962 (5.5%) of the participants not allocated to vitamin
D (HRcrude, 0.94; 95%CI, 0.88–1.00).After adjustments,
risk of death was reduced by 7% (HR, 0.93; 95% CI,
0.88–0.99) during the 3 yr of follow-up in participants
randomized to vitaminDwith orwithout calcium (Fig. 1).
Visual inspection of the survival curve (Fig. 1) indicates
that risk started to diverge quite quickly. However, al-
though risk estimateswere reduced in the groupof vitamin
D-treated participants, risk of death did not differ signif-
icantly between groups after 12 months (HR, 0.96; 95%
CI, 0.86–1.08) or 24 months (HR, 0.94; 95% CI, 0.87–
1.02) of treatment.
Statistically significant interaction terms were whether
vitamin D was coadministrated with calcium (P  0.01),
whereas no significant interactions were found for sex
(P  0.83), age (P  0.08), route of vitamin D adminis-
tration (P0.65), dosing interval (P0.98), or treatment
at baseline with HRT (P 0.46) or bi-
sphosphonates (P  0.16).
Mortality rates differed significantly
between studies investigating the ef-
fects of vitamin D without calcium and
studies on CaD (Table 1). On average,
in the groups of untreated/placebo-
treated participants, 4.4% died in the
CaD trials, whereas 9.7% died in the
studies on vitamin D alone (P 0.01).
Effects of concomitant calcium
administration
Restricting the analysis to studies
withCaD supplementation (13–15, 19,
21), risk of death was significantly re-
duced among participants randomized
to CaD (HR, 0.91; 95% CI, 0.84–
0.98). Exclusion of participants from
the placebo/non-vitamin D group who
were treated with calcium alone (n 
1311) didnot change the results (HR,0.92; 95%CI, 0.85–
1.00; P  0.05) (Fig. 2).
On the other hand, restricting the analysis to the four
studies on vitamin D alone (11, 15, 18, 20), risk of death
didnot differ according to treatment allocation (HR,0.96;
95% CI, 0.87–1.06). Removal of the participants treated
with calcium alone did not change the results (Fig. 2).
Neither did vitamin D affect mortality if analyses were
restricted to include only studies using cholecalciferol
(HR, 0.94; 95% CI, 0.83–1.06).
Dose-effect relationships
As shown in Fig. 3, no statistically significant dose-
effect relationships were evident. Most estimates showed
FIG. 2. IPD analysis on survival in participants randomized to vitamin D alone (left) or vitamin
D with calcium (right) vs. placebo/no supplements. For the RECORD study, participants treated
with calcium without concomitant vitamin D (n  1311) were excluded, whereas the placebo
group (n  1332) was included in both analyses. Data represent adjusted HR (95% CI). *, P 
0.05.
FIG. 3. IPD analysis on dose-effect relationships of vitamin D
treatment on risk of death. Note that none of the included studies
used a daily dose between 10 and 20 g. All studies and stratified by
whether vitamin D was provided alone (Vit D alone) or in combination
with calcium (Vit D  calcium). Data represent adjusted HR (95% CI).
The Smith study using an average daily dose of 20 g vitamin D2 was
regrouped into the low-dose (10 g/d) group.
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a reduced risk, but mortality was only significantly re-
duced in participants treated with a daily dose of 10 g
vitamin D in combination with calcium (HR, 0.90; 95%
CI, 0.83–0.99).
Daily vs. intermittent administration
Two studies provided data on intermittent (once-a-
year) administration of either ergocalciferol (18) or chole-
calciferol (20), which did not affect mortality (HR, 0.97;
95% CI, 0.83–1.12), whereas mortality was significantly
decreased in participants randomized to receive daily sup-
plements (HR,0.93; 95%CI, 0.86–0.99).However, daily
treatment with vitamin D without calcium did not affect
mortality (HR, 0.95; 95% CI, 0.84–1.08), whereas mor-
tality was reduced in participants randomized to daily
CaD (HR, 0.91; 95% CI, 0.84–0.98).
Sensitivity analyses
Influence analyses showed only minor effects of exclu-
sion of studies one by one (Fig. 4). Removal of the cluster
randomized study by Larsen et al. (13) from the analysis
on CaD trials did not change the results (HR, 0.88; 95%
CI, 0.77–0.99).
In analyses not accounting for whether calcium was
coadministrated, mortality was borderline significantly
reduced if analyses were restricted to only double-blind
studies (Pinteraction 0.05; HR, 0.92; 95%CI, 0.85–1.00)
(11, 15, 18–20) and significantly reduced if analyses were
further restricted to include only individually randomized
double-blind studies (Pinteraction  0.02; HR, 0.89; 95%
CI, 0.81–0.98) (15, 18–20). Within the group of individ-
ually randomized double-blind studies, mortality was sig-
nificantly reduced in response toCaD (HR, 0.83; 95%CI,
0.73–0.95) (15, 19), but not in response to vitamin D
alone (HR, 0.96; 95% CI, 0.85–1.09) (15, 18, 20). Re-
stricting analyses to include data from only open-label
trials showed no significant effects on mortality (HR,
0.95; 95% CI, 0.86–1.05) (13, 14, 21).
Analyses not accounting for study duration
Althoughmost included studies only provided data for
a 3-yr intervention period, some studies had a longer du-
ration (Table 1). Including all deaths occurring during
studies (n  5526), logistic regression analysis (adjusted
for indices included in the base model) showed no statis-
tical significant effects on mortality in participants ran-
domized to vitaminDwith or without calcium (OR, 0.96;
95%CI, 0.90–1.01).However, stratificationby coadmin-
istration of calcium (Pinteraction 0.01) showed a reduced
mortality in the CaD trials (OR, 0.93; 95% CI, 0.87–
0.99), but not if vitamin D was given alone (OR, 0.98;
95% CI, 0.89–1.09).
Absolute risk reduction and numbers needed to
treat
Because vitaminD alonewas not shown to reducemor-
tality significantly, we did this analysis only for the CaD
studies.Over 3 yr of follow-up, the absolute risk reduction
was 0.66% (untreated event rate, 16 per 1000 person
years), i.e. 151 persons should be treated for 3 yr to pre-
vent one death.
Trial level meta-analysis
As shown in Fig. 5A, trial level meta-analysis of in-
cluded studies from the IPD analysis showed results sim-
ilar to the IPD analysis with a reduced risk of death in
participants randomized to CaD (HR, 0.93; 95% CI,
0.87–0.99). Extending the analysis to include additional
data from large- andmedium-sized studies not included in
the IPD analysis (Table 1) showed similar results (Fig. 5B).
Finally, resultswere not changedby extending the analysis
to include data from all studies shown in Table 1. This
analysis included data on a total of 88,097 randomized
participants, among whom 28,212 were included in 12
trialswith vitaminDaloneand59,885were included in13
trials onCaD.Overall,mortalitywas significantly reduced
(P  0.04) in participants randomized to treatment with
vitamin D with or without calcium (OR, 0.95; 95% CI,
0.91–1.00). Stratification by coadministration of calcium
showed reduced mortality in participants randomized to
CaD (OR, 0.94; 95% CI, 0.88–0.99), but not in partici-
pants treated with vitamin D alone. Influence analyses
with removal of studies one by one did not change risk
estimates to any major degree, although mortality was no
longer significantly reduced in response to CaD if the
Larsen et al. (13) trial (HR, 0.94; 95% CI, 0.86–1.03) or
the WHI (19) study (HR, 0.95; 95% CI, 0.87–1.03) was
removed fromanalyses (Supplemental Fig. 1, publishedon
TheEndocrine Society’s JournalsOnlineweb site at http://
jcem.endojournals.org). Removal of the cluster random-
ized trial by Law et al. (16) showed results similar to the
FIG. 4. Sensitivity analysis: influence of removing individual studies
from the IPD analysis stratified by whether vitamin D (Vit D) was
provided alone or in combination with calcium (Vit D  calcium). Data
represent adjusted HR (95% CI). w/o, Without.
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overall analysis with no effect of vitamin D alone (Sup-
plemental Fig. 1). Restricting the trial level analysis to
include only individually randomized double-blind stud-
ies (9, 10, 12, 15, 17–20, 27–32), mortality was reduced
overall (OR, 0.94; 95% CI, 0.89–0.99). Stratification by
coadministration of calcium showed a significantly (P 
0.05) reduced mortality in response to CaD (OR, 0.93;
95% CI, 0.86–1.00), but not with vitamin D alone (OR,
0.95; 95% CI, 0.89–1.03).
Discussion
In a pooled analysis, including data at the level of the indi-
vidual frommore than70,000elderlyparticipants,mortality
was significantly reducedduring3yrof treatmentwithCaD,
whereasvitaminDalonedidnotaffectmortality.These find-
ings were further supported by a trial level meta-analysis.
Contrast with previous reviews of vitamin D with or
without calcium, and calcium alone on mortality
In the 2007 trial level meta-analysis of vitamin Dwith or
without calcium and mortality, including 18 trials without
size limitwitha totalof57,311participants,AutierandGan-
dini (4) found a risk ratio of 0.93 (95%CI, 0.87–0.99). The
results did not appear to be influenced by whether calcium
was provided or not, dose of vitaminD, or length of follow-
up. Our IPD analysis included four large trials not included
intheAutierandGandini review(4).Chungetal. (2)updated
the Autier andGandini review (4) but used different inclu-
sion criteria and found a risk ratio of 0.97 (95% CI,
0.92–1.02) for vitamin D alone (13,833 participants,
four trials) and a risk ratio of 0.93 (95%CI, 0.86–1.01)
for CaD (44,688 participants, 11 trials). Thus, although
their results were not statistically significant for any
comparison, the trendswere similar to those found here.
In accordance with our results, in the 2009 Cochrane
review of vitaminD for the prevention of fractures only, the
risk ratio for mortality was 1.01 (95% CI, 0.95–1.06) for
vitaminDtrialswith statistical evidenceofheterogeneity (Ph-
eterogeneity 0.04; I2 68%) and 0.94 (95%CI, 0.89–0.99)
for trials with CaD, with little statistical evidence for heter-
ogeneity of effect (Pheterogeneity 0.70; I
2 0%) (5).
Contrast between vitamin D plus calcium and
vitamin D alone results
Reduced mortality with CaD, but not with vitamin D
alone could suggest that the reducedmortality is due to an
FIG. 5. Trial level meta-analyses (random effect model) of studies included in the IPD analysis (A) and meta-analysis including additional large- and
medium-sized studies (B). For studies included in the IPD, all deaths occurring during trials were accounted for as detailed in Table 1.
1)No between-study heterogeneity was evident for studies on vitamin D with calcium (P  0.46; I2  0%), vitamin D without calcium (P  0.86;
I2  0%) or the overall effect (P  0.69; I2  0%). Influence analyses showed no statistically significant effect of treatment if the WHI study (19)
(OR, 0.94; 95% CI, 0.86–1.03) or the Larsen et al. (13) study (OR, 0.94; 95% CI, 0.86–1.02) was removed from the analysis.
2)No between-study heterogeneity was evident for studies on vitamin D with calcium (P  0.37; I2  8%), vitamin D without calcium (P  0.30;
I2  16%), or the overall effect (P  0.30; I2  13%). Influence analyses showed no effects of removal of studies one by one, except for removal
of the Porthouse et al. (14) study, leaving a statistically significant (P  0.02) risk estimate for the remaining seven studies (OR, 0.92; 95% CI,
0.87–0.99). Effect size changed slightly by removal of the cluster randomized studies by Larsen et al. (13) (OR, 0.95; 95% CI, 0.88–1.04) and by
Law et al. (16) (OR, 0.96; 95% CI, 0.89–1.03).
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effect of calcium rather than vitamin D. However, two
recent IPD analyses and trial level meta-analyses by Bol-
land et al. (23, 33) show an increased risk of myocardial
infarction with calcium, with or without vitamin D. So
how can CaD reduce mortality when vitamin D alone ap-
pears not to be an influence and calcium alone may in-
crease cardiovascular morbidity? There are several possi-
ble explanations. First, the reported 30% increase in
myocardial infarction from calcium supplementation
would have only a small effect on overall mortality (23).
For example, in the United Kingdom, myocardial infarc-
tion is responsible for 6.4%of all deaths inwomenover 75
yr of age; thus, a 30% increase in mortality would have a
very small effect on overall mortality (19). Secondly, com-
peting risks for disease may be another explanation. Cal-
cium supplementation could reduce recurrence of colo-
rectal adenomas and thus colorectal cancer and mortality
(34), an effect thatmaybe strengthened if vitaminD is also
provided (35). Calciumand vitaminDmay reduce the risk
of cancer, particularly breast and colorectal cancer (36).
Calcium supplementation has some effect in preventing
osteoporotic fractures, although probably not hip frac-
tures, the most important direct cause of osteoporosis
mortality (37).However, becausewe adjusted for incident
hip and spine fractures, the reducedmortality in our anal-
ysis is most likely not attributable to a lower risk of frac-
ture (and deaths after fractures). Thirdly, CaD may have
effects when given together greater than their individual
effects. Several studies have shown associations between
high plasma levels of PTH and the risk of different (in-
cluding cardiovascular) diseases and mortality (38, 39).
Calcium, as well as vitamin D, is known to lower PTH
levels. The doses of vitamin D tested in the vitamin D-
alone studies were possibly too low to affect PTH levels,
whereas PTH levels were lowered in response to CaD.
Because PTH levels were notmeasured systematically in
the included trials, we were unable to test this hypoth-
esis. Fourthly, the vitamin D trials may have selected
doses and methods of administration that were not ad-
equate; in addition, the participants included in the vi-
tamin D-alone trials were older than those included in
the CaD trials. Our data do not exclude that treatment
(vitamin D with or without calcium) is only effective in
the early stages of a disease. Finally, differences in the
ascertainment of events between the Bolland et al. (23,
33) meta-analyses and the robust ascertainment of
death might be another explanation.
Hazard rates started to diverge quite quickly in our IPD
analysis, as shown inFigs. 1 and2.Unfortunately,wewere
unable to evaluate the causes of death in response to the
use of supplements. Epidemiological studies have sug-
gested that vitamin D and calcium may affect many dif-
ferent organ systems and health outcomes, including in-
fections, cardiovascular health, autoimmunediseases, and
malignancies (3). Our analyses suggest that supplementa-
tion with CaD starts to affect general health early, which
is sustained during long-term treatment. Our data do not
allow for conclusions on whether this is due to an imme-
diate and sustained effect or whether harm/benefit ratios
for certain health outcomes change over time.
Limitations of our analysis
Although it contributes a systematic appraisal of im-
portant confounders that may contribute to the difference
in survival effects found in clinical trials, the present anal-
ysis has important limitations.
Overall, despite a large sample size, the IPD analysis
cannot correct potential flaws of the original studies, e.g.
in design and compliance with medication. Additional
limitations are imposed by the limited set of variables that
had been addressed in a fairly consistent way across stud-
ies. In general, large CaD trials have been conducted with
limited funding, and this imposed limitations on the num-
ber of variables that could be collected and the degree of
adjudication on exposures and outcomes performed. Al-
though vitaminD can be split into two dose groups (about
10g/dandabout20g/d, respectively), and some studies
gave calcium whereas others did not, the pooled study
population does not create a true factorial design of four
study armswell matched for age, sex, and risk factors. For
example, only the RECORD study (15)—a tertiary pre-
vention study for osteoporosis, because all patients had
prior fractures—used daily oral vitamin D at the 20 g/d
dose without calcium. It is possible that the lack of effect
in the patient level analysis regarding vitamin D given
alone is influencedmore by the design of the trials than by
the active intervention itself.Of the four studies, the Smith
et al. (18) and Sanders et al. (20) studies (once yearly high-
dose treatment)may have been influenced by too high and
long a dosing interval, the RECORD study (15) by the use
of calcium in the control arm and poorer compliance, and
the Meyer study (11) by the low dose of vitamin D. Our
findings showed a significantly reduced mortality if CaD
was administrated daily, whereas no effect was evident if
vitaminDwas administrated intermittently.However, be-
cause the test on interaction between daily vs. intermittent
administration was insignificant, our data do not exclude
that the lack of an effect may be due to an insufficient
statistical power, e.g. too few participants in the group
receiving vitamin D intermittently. Several of the risk
estimates on the effects of vitamin D alone were below
1.00, with an upper limit of the CI only slightly above
1.00, which may indicate potential beneficial effects of
vitamin D alone. However, because the results did not
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reach strict statistical significance, we think that our
results should only be interpreted in such a way that
they should encourage further exploration of whether
such effects are present.
In the IPD analysis, information on adherence, self-
administered CaD supplements, and baseline dietary cal-
cium and vitamin D intake was not consistently available,
so this could not be accurately addressed. Accordingly,we
were not able to perform a per-protocol analysis. How-
ever, our intention-to-treat analytical approach probably
offers a more realistic measure of what can be achieved by
applying such measures in the general population of el-
derly participants at risk of fracture than more intensive
studies. In accordance,we chose to include all randomized
studies in our primary analyses independently of the na-
ture of randomization.Although cluster randomized stud-
ies may be prone, for example, to selection bias (40), the
less rigorous design may more accurately reflect the real-
world circumstances because study participants are nor-
mally not required to fulfill a number of individual criteria
for participation. Nevertheless, analyses including only
individually randomized controlled studies showed re-
sults similar to the overall analyses, indicating that inclu-
sion of non-individually randomized studies did not
change the overall findings.Anadditional limitation in the
IPD analysis was the restricted time frame of 3 yr. Nev-
ertheless, extending our IPD analysis to include all deaths
occurring during the entire duration of the eight trials did
not change the overall results, which was further sup-
ported by the trial levelmeta-analysis for all deaths during
the entire duration of the trials.
Within theCaD trials, a significantly reducedmortality
was only shown for the low dose of vitamin D. Our anal-
yses did not indicate that a higher dose (20 g/d) is in-
ferior to a lower daily dose. Rather,most risk estimates on
adaily dose of at least 20gof vitaminDalonewere lower
than with a daily dose of 10 g. In addition to differences
in average age between studies on effects of CaD or vita-
min D alone, it should be emphasized that the primary
endpoint in all studieswas fracturepreventionand that the
different studies included different groups of participants.
In some studies, effects of supplements were studied in the
general population of elderly participants (13, 18–21),
whereas other studies investigated supplements for sec-
ondary (11, 14) or tertiary (15) fracture prophylaxis. Vi-
tamin D status before study entry may have differed be-
tween studies, and effects of vitamin D supplementation
with or without calcium may depend on vitamin D status
(and daily calcium intake). We cannot exclude the possi-
bility that such characteristics, inherited in the design of
the original studies, may affect mortality and may have
influenced effects of vitamin D (and calcium). Epidemio-
logical studies have suggested that mortality may be in-
creased inparticipantswith lowvitaminD levels, although
high levels could be harmful as well (41). It remains un-
known whether this is due to the biological effect of vita-
minD or due to confounders that it may not be possible to
adjust fully for in epidemiological studies. Because plasma
25-hydroxyvitamin D levels were not measured and cal-
cium intake was not assessed consistently at baseline or
during follow-up in the trials included, unfortunately our
data do not allow for further clarification on this matter.
In our study, we adjusted for incident fractures during
trials to assess effects beyond an effect due to a reduced
mortality caused by fewer fractures in response to treat-
ment. Interestingly, antiresorptive treatments with bis-
phosphonates, strontium ranelate, or denosumab have
been shown to reduce mortality, often to a greater extent
than is explained by the reduction in fracture risk (42).
Further studies are needed to investigate possible interre-
lationships between these findings.
In conclusion, our IPD analysis and trial level meta-
analysis consistently showed reduced mortality in elderly
participants randomized to vitamin D supplements in
combination with calcium, whereas the analyses based on
existing interventions and trial populations did not sup-
port an effect of vitamin D alone. Accordingly, calcium
with vitamin D supplementation to elderly participants is
overall not harmful to survival, and may have beneficial
effects on general health.
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